# Aura Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aura-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aurabiosciences.com
- Total disclosed funding: $153M
- Latest round: Series E (Mar 18, 2021)
- Investors on record: 15

## About

Aura Biosciences, Inc. is a Boston-based company focused on developing targeted oncology therapies, leveraging its proprietary Virus-Like Drug Conjugate technology to treat rare cancers such as choroidal melanoma.Founded in 2009 in Boston, US, Aura Biosciences, Inc. specializes in innovative oncology treatments. The company is led by CEO Elisabet de los Pinos. Its recent funding round on May 14, 2025, raised USD 75 mn, bringing the total amount raised to USD 75 mn across 16 deals.Aura Biosciences develops targeted therapies in oncology, utilizing its Virus-Like Drug Conjugate (VDC) technology. Its leading product, Belzupacap sarotalocan, targets early-stage choroidal melanoma. The company is also expanding its pipeline to include therapies for choroidal metastasis and bladder cancer, primarily serving oncologists and healthcare institutions in the US and Europe.Aura Biosciences generates revenue through partnerships with academic institutions and healthcare organizations, focusing on its VDC products. The business model targets B2B sales to hospitals and clinics, with revenue stemming from the sale of its VDCs and potential licensing agreements with pharmaceutical companies.In May 2025, Aura Biosciences raised USD 75 mn in a private placement, selling shares on Nasdaq. The company plans to utilize this funding to advance its product pipeline, including the launch of new therapies targeting additional cancer indications, and to expand into European markets by 2026, addressing unmet medical needs in oncology.

## Funding rounds

- Series E, Mar 18, 2021, $80M — Adage Capital Management, Ysios Capital Partners, Lundbeckfond Ventures, Velocity Fintech Ventures, Rock Springs Capital, Matrix Capital Management, Chiesi Ventures, Medicxi, Arix Bioscience, Advent Life Sciences, Columbus Venture Partners, Surveyor Capital
- Series D, Apr 2, 2019, $20M — Alexandria Venture Investments, Lundbeckfond Ventures, Chiesi Ventures, Medicxi, Arix Bioscience, Advent Life Sciences, LI-COR, Inc., Columbus Venture Partners
- Series C, Dec 21, 2017, $32M — Alexandria Venture Investments, Ysios Capital Partners, Lundbeckfond Ventures, Columbus Venture Capital, Chiesi Ventures, Arix Bioscience, Advent Life Sciences, LI-COR, Inc.
- Series B, Feb 24, 2015, $21M — Alexandria Venture Investments, Ysios Capital Partners, Chiesi Ventures, Advent Life Sciences

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C, Series D
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series B, Series C, Series E
- Chiesi Ventures (https://capitalatlas.ai/funds/chiesi-ventures) — Series B, Series C, Series D, Series E
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B, Series C, Series D, Series E
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series C, Series D, Series E
- Columbus Venture Capital — Series C
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series C, Series D, Series E
- LI-COR, Inc. — Series C, Series D
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series D, Series E
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series D, Series E
- Adage Capital Management — Series E
- Velocity Fintech Ventures — Series E
- Rock Springs Capital — Series E
- Matrix Capital Management — Series E
- Surveyor Capital — Series E